Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: October-22-12
Credit Expiration Date: October-21-13

Faculty

B. Douglas Smith, MD
Associate Professor, Hematologic Malignancies
Kimmel Cancer Center
Johns Hopkins
Baltimore, MD

Credit Hours

0.50 AMA PRA Category 1 Credit

Medium

Mobile + Online on QuantiaMD

Program Description

Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem cells that accounts for approximately 15% of all adult leukemias. Historical treatment of this condition included allogeneic stem cell transplant (SCT), interferon-α, (INF-α), and low-dose cytosine arabinoside (araC). The discovery of the BCR-ABL kinase fusion protein and its role in the pathogenesis of CML has led to the emergence of targeted therapy, which has now become the standard of care for patients with this disease.

The recent changes to standard therapy, combined with the development of novel CML agents, have led to challenges with regard to escalation and transition of therapy and management of treatment-related side effects. It is clear that increased knowledge and application of contemporary CML guidelines, combined with enhanced capabilities of clinicians to effectively manage side effects and utilize novel CML therapies, would result in improved CML outcomes and reduced burden to the health care system. It is therefore imperative that hematologists/oncologists receive additional education on optimal strategies for CML diagnosis, treatment, and management.

The goal of this continuing education activity is to expand the ability of oncologists and related clinicians to adequately treat and manage CML.

Program Developer/Facilitator


.

Target Audience

This educational activity is designed to meet the needs of oncologists, hematologists, and medical professionals interested and involved in the treatment of patients with CML.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Define response criteria and their impact on treatment choices in CML.
  2. Review next steps in managing patients with CML who exhibit imatinib resistance or poor response.
  3. List pertinent factors for selecting second-line therapy for patients with CML.
  4. Describe emerging treatment options and strategies for CML.

Disclosures

It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity.

Dr. Smith discloses the following:
Consultant: Bristol-Myers Squibb, Novartis
Data Safety Monitoring Board: Bristol-Myers Squibb



Office of CME:
Zalman S. Agus, MD, has no relevant financial relationships to disclose.
Mila Kostic has no relevant financial relationships to disclose.

MCM Education:
Sara Thier, PhD, MPH, has no relevant financial relationships to disclose.

Investigational and/or Off-Label Use of Commercial Products and Devices :
The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications. In this educational activity, the faculty will not be discussing the investigational use of agents or devices.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and Medical Communications Media, Inc. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.

The Perelman School of Medicine at the University of Pennsylvania designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release date: October 22, 2012
Last review date: October 22, 2012
Expiration date: October 21, 2013

Commercial Support Statements

Supported by an independent educational grant from Teva Oncology.

Instructions

Completion Instructions

  1. Accessing Activity:
    * Link to and Log into program on QuantiaMD.com
    * Take the pre-test
    * Review the activity
    * Take the post-test and score 75%
    * You are allowed two retakes
    * Complete the evaluation
    * View, print, or save a CME certificate verifying your
    credit/participation in this activity
  2. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee

$0.00

There is no charge for CME credit.

Disclaimer

© 2012, MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher,the Perelman School of Medicine at the University of Pennsylvania, or Teva Oncology. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS